Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Tamoxifen biotransformation is associated with higher disease relapse risk and hot flashes
February 23rd, 2006
Tamoxifen biotransformation is associated with higher disease relapse risk and hot flashes. Scientists writing in the Journal of Clinical Oncology wrote, "Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown. We determined cytochrome P450 (CYP)2D6 (*4 and *6) and CYP3A5 (*3) genotype from paraffin-embedded tumor samples and buccal cells (living patients) in tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast cancer trial." "The relationship between genotype and disease outcome was determined using the...
Source: Women's Health Weekly (2006-02-23)
|
